Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction

With the gradual prolongation of the overall survival of cancer patients, the cardiovascular toxicity associated with oncology drug therapy and radiotherapy has attracted increasing attention. At present, the main methods to identify early cancer treatment-related cardiac dysfunction (CTRCD) include...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huiyu Xiao, Xiaojie Wang, Shuang Li, Ying Liu, Yijie Cui, Xiaoqin Deng
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	cancer treatment-related cardiac dysfunction biomarkers cardio-oncology anthracyclines HER2-targeted therapy immune checkpoint inhibitors Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/d8c62d5d835547c9919d7652bbbe34d0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d8c62d5d835547c9919d7652bbbe34d0
record_format	dspace
spelling	oai:doaj.org-article:d8c62d5d835547c9919d7652bbbe34d02021-11-10T06:59:22ZAdvances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction2297-055X10.3389/fcvm.2021.753313https://doaj.org/article/d8c62d5d835547c9919d7652bbbe34d02021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.753313/fullhttps://doaj.org/toc/2297-055XWith the gradual prolongation of the overall survival of cancer patients, the cardiovascular toxicity associated with oncology drug therapy and radiotherapy has attracted increasing attention. At present, the main methods to identify early cancer treatment-related cardiac dysfunction (CTRCD) include imaging examination and blood biomarkers. In this review, we will summarize the research progress of subclinical CTRCD-related blood biomarkers in detail. At present, common tumor therapies that cause CTRCD include: (1) Chemotherapy—The CTRCD induced by chemotherapy drugs represented by anthracycline showed a dose-dependent characteristic and most of the myocardial damage is irreversible. (2) Targeted therapy—Cardiovascular injury caused by molecular-targeted therapy drugs such as trastuzumab can be partially or completely alleviated via timely intervention. (3) Immunotherapy—Patients developed severe left ventricular dysfunction who received immune checkpoint inhibitors have been reported. (4) Radiotherapy—CTRCD induced by radiotherapy has been shown to be significantly associated with cardiac radiation dose and radiation volume. Numerous reports have shown that elevated troponin and B-type natriuretic peptide after cancer treatment are significantly associated with heart failure and asymptomatic left ventricular dysfunction. In recent years, a few emerging subclinical CTRCD potential biomarkers have attracted attention. C-reactive protein and ST2 have been shown to be associated with CTRCD after chemotherapy and radiation. Galectin-3, myeloperoxidas, placental growth factor, growth differentiation factor 15 and microRNAs have potential value in predicting CTRCD. In this review, we will summarize CTRCD caused by various tumor therapies from the perspective of cardio-oncology, and focus on the latest research progress of subclinical CTRCD biomarkers.Huiyu XiaoXiaojie WangShuang LiYing LiuYijie CuiXiaoqin DengFrontiers Media S.A.articlecancer treatment-related cardiac dysfunctionbiomarkerscardio-oncologyanthracyclinesHER2-targeted therapyimmune checkpoint inhibitorsDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cancer treatment-related cardiac dysfunction biomarkers cardio-oncology anthracyclines HER2-targeted therapy immune checkpoint inhibitors Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	cancer treatment-related cardiac dysfunction biomarkers cardio-oncology anthracyclines HER2-targeted therapy immune checkpoint inhibitors Diseases of the circulatory (Cardiovascular) system RC666-701 Huiyu Xiao Xiaojie Wang Shuang Li Ying Liu Yijie Cui Xiaoqin Deng Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction
description	With the gradual prolongation of the overall survival of cancer patients, the cardiovascular toxicity associated with oncology drug therapy and radiotherapy has attracted increasing attention. At present, the main methods to identify early cancer treatment-related cardiac dysfunction (CTRCD) include imaging examination and blood biomarkers. In this review, we will summarize the research progress of subclinical CTRCD-related blood biomarkers in detail. At present, common tumor therapies that cause CTRCD include: (1) Chemotherapy—The CTRCD induced by chemotherapy drugs represented by anthracycline showed a dose-dependent characteristic and most of the myocardial damage is irreversible. (2) Targeted therapy—Cardiovascular injury caused by molecular-targeted therapy drugs such as trastuzumab can be partially or completely alleviated via timely intervention. (3) Immunotherapy—Patients developed severe left ventricular dysfunction who received immune checkpoint inhibitors have been reported. (4) Radiotherapy—CTRCD induced by radiotherapy has been shown to be significantly associated with cardiac radiation dose and radiation volume. Numerous reports have shown that elevated troponin and B-type natriuretic peptide after cancer treatment are significantly associated with heart failure and asymptomatic left ventricular dysfunction. In recent years, a few emerging subclinical CTRCD potential biomarkers have attracted attention. C-reactive protein and ST2 have been shown to be associated with CTRCD after chemotherapy and radiation. Galectin-3, myeloperoxidas, placental growth factor, growth differentiation factor 15 and microRNAs have potential value in predicting CTRCD. In this review, we will summarize CTRCD caused by various tumor therapies from the perspective of cardio-oncology, and focus on the latest research progress of subclinical CTRCD biomarkers.
format	article
author	Huiyu Xiao Xiaojie Wang Shuang Li Ying Liu Yijie Cui Xiaoqin Deng
author_facet	Huiyu Xiao Xiaojie Wang Shuang Li Ying Liu Yijie Cui Xiaoqin Deng
author_sort	Huiyu Xiao
title	Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction
title_short	Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction
title_full	Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction
title_fullStr	Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction
title_full_unstemmed	Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction
title_sort	advances in biomarkers for detecting early cancer treatment-related cardiac dysfunction
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/d8c62d5d835547c9919d7652bbbe34d0
work_keys_str_mv	AT huiyuxiao advancesinbiomarkersfordetectingearlycancertreatmentrelatedcardiacdysfunction AT xiaojiewang advancesinbiomarkersfordetectingearlycancertreatmentrelatedcardiacdysfunction AT shuangli advancesinbiomarkersfordetectingearlycancertreatmentrelatedcardiacdysfunction AT yingliu advancesinbiomarkersfordetectingearlycancertreatmentrelatedcardiacdysfunction AT yijiecui advancesinbiomarkersfordetectingearlycancertreatmentrelatedcardiacdysfunction AT xiaoqindeng advancesinbiomarkersfordetectingearlycancertreatmentrelatedcardiacdysfunction
_version_	1718440515853090816

Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction

Ejemplares similares